Personalized Vaccines Plus Checkpoint Inhibitors Proposed as a New Therapeutic Frontier for Endometriosis
核心洞察
Endometriosis (搜索) affects approximately 200 million women and girls globally, causing chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility with high recurrence rates despite hormonal suppression and surgery.
Ectopic endometriotic lesions harbor recurrent somatic mutations in cancer-associated genes such as KRAS (搜索), PIK3CA, ARID1A (搜索), PPP2R1A (搜索), and PTEN (搜索), with higher mutant allele frequencies than matched eutopic tissue.
A perspective article proposes combining immune checkpoint inhibitors with personalized vaccines targeting patient-specific somatic mutations, mirroring emerging cancer immunotherapy paradigms.
Endometriosis (搜索)—a debilitating condition marked by the growth of endometrial-like tissue outside the uterine cavity—affects approximately 200 million women and girls worldwide, yet remains under-researched relative to its impact. A new perspective published in the International Journal of Women's Health proposes that the disease's recently characterized somatic mutations and immunosuppressive microenvironment could be exploited therapeutically, drawing on paradigms already transforming cancer care.
The proposal centers on combining immune checkpoint inhibition with personalized vaccination targeting patient-specific somatic mutations in endometriotic lesions. The authors frame this as a hypothesis-generating conceptual model intended to stimulate future research rather than an immediately actionable strategy.
Immune Privilege and Immunosuppression in Endometriosis
The eutopic endometrium is a dynamic immunological niche that undergoes cyclical remodeling under the influence of estradiol and progesterone, balancing immune tolerance essential for embryo implantation against immune surveillance. During the secretory phase, rising progesterone induces a tolerogenic shift, with indoleamine 2,3-dioxygenase (IDO) catabolizing tryptophan into immunosuppressive kynurenine. Prostaglandin E2 (PGE2), the predominant prostaglandin in the endometrium, further promotes T helper 2 (Th2), T helper 17 (Th17), and regulatory T cell (Treg) responses while suppressing type-1 immunity.
Notably, IDO expression is elevated in both eutopic and ectopic endometrium in individuals with endometriosis (搜索), and PGE2 levels are higher in the menstrual fluid of affected women. "Together, these factors likely heighten an already preconditioned immunosuppressive environment and facilitate the survival of aberrant endometrial cells," the authors write.
Ectopic lesions exhibit a unique immune microenvironment that suppresses cytotoxic responses. Tregs are enriched and secrete IL-10 and TGF-β to inhibit effector T cells, while M2 macrophages dominate and produce VEGF and matrix metalloproteinases. Checkpoint pathways including PD-1 (搜索)/PD-L1 (搜索), CTLA-4 (搜索)/CD80/CD86, TIM-3/Gal-9, and CD47/SIRPα are documented to be dysregulated in endometriosis (搜索), mirroring tumor microenvironments.
Somatic Mutations as Potential Therapeutic Targets
Recent studies have revealed that the eutopic endometrium is not genetically uniform but comprises a mosaic of clonal epithelial populations harboring distinct somatic mutations in cancer-associated genes, including KRAS (搜索), PIK3CA, ARID1A (搜索), PPP2R1A (搜索), and PTEN (搜索). In a key study, Suda and colleagues sequenced 109 single endometrial glands and found that each gland carried distinct somatic mutations.
Whole-exome sequencing of 13 endometriotic and 11 normal uterine endometrial epithelial samples identified a total of 4,192 somatic mutations, with a median of 128 exonic somatic mutations per sample (range 72 to 536). Mutant allele frequency analyses consistently show higher frequencies in ectopic lesions compared to matched eutopic tissue, indicating clonal expansion under selective pressures.
Ovarian endometriomas exhibit higher frequencies of ARID1A (搜索) and PIK3CA mutations, which are also implicated in endometriosis (搜索)-associated ovarian cancers. A recent longitudinal immunohistochemistry-based study showed that PTEN (搜索) and ARID1A loss were very frequent in endometriosis—68.3% and 24.6%, respectively, at the participant level—with PTEN loss significantly associated with more severe anatomic subtypes.
A Proposal for Combination Immunotherapy
The authors propose that, analogous to the cancer setting, patients with endometriosis (搜索) could benefit from combination therapy including immune checkpoint inhibition and personalized vaccination targeting somatic mutations. This approach would begin with lesion biopsies and deep whole-exome or whole-genome sequencing to identify candidate somatic mutations that might yield targetable neoepitopes, with bioinformatic pipelines such as pVACtools used to predict MHC binding and antigen presentation.
The rationale is supported by preclinical findings. Anti-CTLA4 therapy in mice reduced lesion size and modulated Treg populations, while anti-PD-L1 (搜索) antibody treatment markedly decreased lesion volumes compared to isotype control. In cancer, the combination of personalized vaccines with checkpoint blockade has shown synergistic benefits—for example, mRNA-4157 combined with pembrolizumab approximately halved the risk of cancer recurrence and/or death at a median follow-up of 35 months in resected melanoma.
"Abnormal endometriotic tissue could potentially be targeted with greater specificity and effectiveness than existing systemic therapies," the authors note. However, they caution that identical somatic mutations may also be present within subsets of eutopic endometrial glands, so complete avoidance of effects on normal endometrium cannot currently be assumed.
Limitations and Safety Considerations
Several important uncertainties temper enthusiasm for this approach. The presence of a DNA mutation alone is insufficient to generate an immunogenic target—mutated genes must also be expressed, processed, transported, presented by patient-specific MHC molecules, and recognized by T-cell receptors. Consequently, only a subset of somatic mutations, and perhaps patients, would be expected to generate therapeutically actionable neoantigens.
Safety considerations are particularly important because, unlike malignancy, endometriosis (搜索) is a benign disease and acceptable treatment-associated risks are substantially lower. "Potential immune-related toxicities or side-effects that may be acceptable in life-threatening cancers would require considerably greater justification in a chronic non-malignant condition," the authors write, citing fertility, implantation, pregnancy, menstrual physiology, and long-term reproductive health as key considerations.
The costs of personalized vaccine regimens are currently very high—estimated at over $100,000 per patient in 2025—though these are expected to reduce by orders of magnitude as the technology transitions to routine production.
Direct evidence demonstrating naturally presented neoantigens or efficacy of mutation-directed vaccination in endometriosis (搜索) is currently lacking. The authors conclude that future studies should include deep sequencing of multiple lesions and matched eutopic endometrium, lineage mapping, immunopeptidomics, neoantigen-specific T-cell assays, organoid systems, and humanized animal systems before such approaches can be considered realistic therapeutic options.